Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLC

Overview

Sponsor-declared trial summary

Key facts

Sponsor

PDC line pharma

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

9 Jan 2020 → 30 Sep 2025

Decision date (initial)

2024-10-29

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

Funding sources

PDC*line Pharma SA · PDC*line Pharma SAS

External identifiers

EU CT number

2024-517429-24-00

EudraCT number

2018-002382-19

ClinicalTrials.gov

NCT03970746

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Pharmacodynamic, Safety, Efficacy, Dose response, Therapy

Assess safety and tolerability of PDC*lung01 vaccinations administered at two dose levels as single agent or during maintenance treatment by pemetrexed (for adenocarcinomas in Cohorts A1 and A2) or during treatment with anti-PD-1 therapy (Cohorts B1 and B2).

Secondary objectives 5

1. Evaluate the safety of the combined use of PDC*lung01 with anti-PD-1 therapy
2. Document additional indicators of safety / tolerability
3. Evaluate the humoral allogeneic immune response against PDC*line cells
4. Evaluate the specific T-cell response against the antigens borne by PDC*lung01 vaccine
5. Document preliminary clinical activity

Conditions and MedDRA coding

Non-small-cell lung cancer

Study design 1 period

Regulatory references

Scientific advice from competent authorities

European Medicines Agency, Federal Agency For Medicines And Health Products, Agence Nationale De Sante Publique

Plan to share IPD

No

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 13

1. Pre-screening: Documented HLA-A*02:01 positivity and absence of anti-HLA antibodies against HLA molecules expressed by the PDC*line (See protocol section 14.9.2), after the patient has provided written informed consent. Only patients meeting the above 2 criteria in pre-screening will be allowed to enter the screening period.
2. Patients with histologically proven, or cytologically proven, non-small-cell lung cancer (NSCLC). The stage of the disease is evaluated according to the classification of the American Joint Committee on Cancer, 8th edition (see protocol section 24.1) a. For the dose-escalation phase (Cohorts A1 and A2): a period of at least 4 weeks after last SOC treatment administration/standard therapeutic intervention is required before first study dose administration: (i) Stage IIa/IIb/IIIa NSCLC following radical surgery (R0 resection) and, if applicable, following adjuvant platinum-based chemotherapy, or (ii) Stage IV histologically or cytologically confirmed case of epidermoid (squamous) lung cancer following 4 courses of platinum-based therapy, if targeted treatment options were not indicated or (iii) Stage IV histologically or cytologically confirmed case of adenocarcinoma (non-squamous) lung cancer following 4 to 6 cycles of pemetrexed and platinum combination, if targeted treatment options were not indicated (iv) Populations (ii) and (iii) who have stopped prematurely chemotherapy, after at least 2 cycles of platinum-based therapy, for any reason, AND do present with a documented stable disease or partial / complete response. b. For the anti-PD-1 immunotherapy (Cohorts B1 and B2): The patient has first-line metastatic stage IV NSCLC measurable disease and is starting anti-PD-1. The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%), assuming no targeted mutation detected, following standard NGS testing, if applicable, and thus no targeted treatment option is indicated, must have been made by the investigator before and regardless of the patient’s participation in the study. Radiotherapy/chemoradiotherapy for prior stage III NSCLC is allowed if the treatment-free interval is >1 year.
3. ECOG performance status 0 or 1
4. Adequate renal and hepatic function as defined below: Serum creatinine clearance > 50 mL/min (Cockcroft–Gault formula) • Bilirubin ≤ 1.5 times upper limit of normal (ULN) • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times ULN (up to 5 times ULN are allowed in case of presence of liver metastases)
5. Adequate haematological function as defined below: • Platelet count ≥ 70 × 109 /L; • White blood cell count ≥ 2.5 x 109 /L with  lymphocytes ≥ 1 x 109 /L at screening or at baseline and  absolute neutrophil count ≥ 1.5x109/L; • Haemoglobin ≥ 90 g/L
6. Patient willing to provide a baseline blood sample for leucocyte enumeration, cellular allogeneic response and immune-monitoring of 100 ml in total (in one or two samplings)
7. For patients with brain metastases: • Central nervous system metastases are not symptomatic or have been treated, • Subjects with symptomatic CNS metastases must be either off corticosteroids, or on a stable or decreasing dose of ≤10mg daily prednisone (or equivalent) during at least 2 weeks before baseline
8. For female patients without child-bearing potential: a documentation of tubal ligation or hysterectomy, ovariectomy or a post-menopausal status is available. For female patients of child-bearing potential: a negative serum pregnancy test at screening is required. The patient agrees to use a highly effective contraception method from signing informed consent form (screening), throughout the study treatment period with PDC*lung01 and for at least 28 days after the last administration of PDC*lung01. For female patients receiving Pemetrexed in cohorts A1/A2 concomitantly with PDC*lung01, according to corresponding SmPC, it is required to use effective contraception during treatment with pemetrexed. For female patients receiving Pembrolizumab in cohorts B1/B2 concomitantly with PDC*lung01, according to corresponding SmPC, it is required to use an effective method of contraception up to 4 months thereafter. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. - “Highly effective” contraceptive measures acceptable for the whole duration of the study have been defined based on the CTFGs recommendations on contraception and are the following: − Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), − Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable). − Intrauterine device (IUD) − Intrauterine hormone-releasing system (IUS) − Monogamous relationship with a vasectomized partner. Partner must have been vasectomized for at least 6 months before the participant entered into the study - Abstinence or absence of sexual relations with men
9. Males with reproductive potential should use barrier method of contraception (condom) from signing informed consent form (screening) up to at least 28 days after the last dose of PDC*lung01. For male patients receiving Pemetrexed in cohorts A1/A2 concomitantly with PDC*lung01, according to corresponding SmPC, it is required to use barrier method of contraception up to 6 months thereafter
10. In the Investigator’s opinion, the patient is able and willing to comply with the requirements of the study
11. Patient willing and able to sign the study informed consent form before any study-specific procedures are conducted
12. Patient (male or female) is aged 18 years or above
13. Specific for patients enrolled in France: Patient is affiliated to a health insurance system

Exclusion criteria 13

1. Mixed small-cell and non-small-cell histological features
2. Patient has documented evidence of EGFR mutation, ALK fusion or ROS1 fusion (according to current ESMO clinical practice guidelines) or any mutation for which targeted treatment options would be indicated, as per SoC
3. Patient has received immunotherapy or any investigational drugs within 4 weeks before the first PDC*lung01 dose. Chemoradiotherapy with consolidation durvalumab for prior stage III disease
4. Patient with Stage IV disease that received prior radiotherapy (except palliative radiotherapy e.g. brain irradiation). Palliative radiotherapy for stage IV disease should be completed one week prior to baseline visit and for brain irradiation a 2-week window is required
5. Patient without brain metastasis is receiving systemic corticosteroids at a dose level exceeding 10 mg/day (prednisone or equivalent) during the screening period (administration by nasal spray, topical solution or oral inhaler is non-systemic and is therefore allowed)
6. Patient has a medical history of cancer other than NSCLC, except the following: (i) non-melanoma skin cancer with complete resection, (ii) adequately treated carcinoma in situ, (iii) other cancer treated with no evidence of disease for at least five years with the exception of pT1-2 prostatic cancer Gleason score < 6 and superficial bladder cancer
7. Known hepatitis B and/or C infection (testing not required)
8. Known positive for human immunodeficiency virus (HIV; testing not required)
9. Uncontrolled congestive heart failure or hypertension, unstable heart disease (coronary artery disease with unstable angina or myocardial infarction within 6 months of baseline) or uncontrolled ventricular arrhythmias at the time of enrolment in the study (atrial fibrillation or flutter is acceptable)
10. Any history of splenectomy or splenic irradiation
11. For female patients: pregnancy or lactation
12. Any condition, including autoimmune or immunodeficiency active disease that, in the opinion of the Investigator, would jeopardise patient’s safety, or might compromise the effect of the study drug or the assessment of the study result. Patients with vitiligo, diabetes Type I, psoriasis (not requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, or oral corticosteroids within the previous 12 months) or a history of autoimmune thyroiditis are not excluded
13. Specific for patients enrolled in France: Patient is under legal protection

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Occurrence of dose-limiting toxicities (DLT) related to the administration of PDC*lung01

Secondary endpoints 7

1. Occurrence of serious adverse events (SAEs) and adverse events (AEs), deemed as related to the association of PDC*lung01 and the anti-PD-1 therapy, monitored during study treatment until 28 days after the last dose of PDC*lung01
2. Occurrence of serious adverse events (SAEs) and adverse events (AEs), monitored during study treatment until 28 days after the last dose of PDC*lung01
3. Measurement of anti-HLA class I and II antibodies in the serum. In case of positive detection, the allelic specificity of the antibodies will be determined
4. Ex vivo detection and characterization of CD8+ T cells against tumor antigens borne by PDC*lung01, using flow cytometry
5. Objective Response Rate (according to RECIST version 1.1) for cohort B2
6. Objective Response Rate (according to iRECIST) for cohort B2
7. Progression-Free Survival at 9 months according to RECIST 1.1 and according to iRECIST from the first day of anti-PD-1 antibody administration for cohort B2

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Auxiliary 3

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

PDC line pharma

Sponsor organisation

PDC line pharma

Address

29 Avenue Des Maquis Du Gresivaudan, Bp 35 Bp 35

City

La Tronche Cedex

Postcode

38701

Country

France

Scientific contact point

Organisation

PDC line pharma

Contact name

PDC*line Pharma Contact

Public contact point

Organisation

PDC line pharma

Contact name

PDC*line Pharma Contact

Locations

5 EU/EEA countries · 10 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Summary of results Art. 37(4) CTR

Layperson summary Annex V

Documents 16 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

2 submissions — initial application plus substantial / non-substantial modifications